Carigent Therapeutics is a biotechnology firm involved in the development of therapeutic agents. The company provides a platform for the controlled release of therapeutics, tethering of surface ligands, and targeted therapy to specific physiological sites, as well as the combination of multiple agents into a single vehicle using FDA-approved materials. It was founded in 2007 and is based in New Haven, Connecticut.

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

Bolder BioTechnology focuses on protein engineering within the biotechnology sector. The company develops human protein pharmaceuticals targeting various medical conditions such as hematological and endocrine disorders, cancer, and infectious diseases. Bolder BioTechnology serves the healthcare and biopharmaceutical industries. It is based in Boulder, Colorado.

Synaptic Research LLC is a biotechnology company which conducts research and develops products based on naturally-occurring large protein molecules. Specifically, the company engineers proteins derived from toxins which affect the synaptic junction. A well-known example of such a protein is the Botulinum Neurotoxin, or BoNT. This protein has qualities of targeting and persistence which make it an excellent candidate for further engineering and development of therapeutic and pharmaceutical products.

April 2004, Sensia spun-off from the technologies developed at the Biosensor Group within the National Microelectronics Centre (CNM) of the Spanish National Research Council (CSIC). Concluding research results and availability of biosensing systems already working at lab level originated the proposal of bringing them into commercialisation, after an initial phase of prototyping and industrialisation. This first idea was supported by Genetrix a young biotech company which is interested in developing biosensors for the characterisation and detection of molecular interactions which are relevant in human pathologies. Dr. Pedro Banda, with experience in the semiconductor industry and biosensor technologies, joined in to get in charge of the project.n

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.